Tagged as: Yuflyma

Celltrion to Enter U.S. Humira Biosimilar Market Following Patent Agreement with AbbVie

Celltrion recently announced that it will start selling Yuflyma, an adalimumab biosimilar, in the U.S. in July 2023.  The announcement stems from Celltrion’s recently inked patent agreement with AbbVie which allows Celltrion to market a high-concentration formulation of the drug.  As a company official stated, “By entering the U.S. market…

Read More